surmount-1 tirzepatide non-diabetic obesity trial (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or SURMOUNT Clinical Trials Orals Session

The most common adverse effects associated with therapeutic semaglutide use include gastrointestinal symptoms, which might theoretically occur more rapidly or intensely with direct venous administration

Serious but Rare Side Effects: Pancreatitis : There is a slight risk of developing pancreatitis

Addressing emotional and mental health in weight management involves a comprehensive approach, including behavioral therapy, cognitive restructuring, and emotional support

Ozempic has joined that elite group where the brand name doesnt just sell the product its become synonymous with its entire category. Two-thirds of Americans now say they want to lose weight, Dan Frommer notes in his Consumer Trends deck for 2026